Bioniche Life Sciences Inc. is a Canadian biopharmaceutical company, founded in 1979, that develops, manufactures, and markets proprietary products for three main markets: (1) Human Health; (2) Animal Health; and (3) Food Safety. The Company is commercializing two canine cancer products, and expects to launch the first of these - Immunocidin™ - in North America as early as July 2012. Immunocidin™ is awaiting regulatory approval in both Canada and the USA, as an immunotherapy for the intra-tumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs. There are around 250,000 chemotherapy treatments performed per annum in the USA alone (on dogs). This market exists and, thus, could be quite lucrative for Bioniche. To read more, click here: Bioniche eResearch posts all its reports and articles on its website, www.eresearch.ca, and subscription is FREE. eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network. Contact:eResearch: Bob Weir, CFA, Director of ResearchTelephone: (416) 703-6258 Ext 221; E-mail: email@example.com
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here